🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

David M. Charytan

McGill University Health Centre

ORCID: 0000-0002-3368-247X

Also affiliated with McGill University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.414Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

All-Cause Mortality and Progression to End-Stage Kidney Disease Following Percutaneous Revascularization or Surgical Coronary Revascularization in Patients with CKD

Kidney International Reports(2021)10.1016/j.ekir.2021.03.882
Top 45%
0.414DataRank
Top 45%7 citations

Katya Zelevinsky, Robert Wolf, Sharon‐Lise T. Normand, David M. Charytan

Papers

Driven by 4 papers — median percentile 55. Top paper: “All-Cause Mortality and Progression to End-Stage Kidney Disease Following Percutaneous Revascularization or Surgical Coronary Revascularization in Patients with CKD”.

All-Cause Mortality and Progression to End-Stage Kidney Disease Following Percutaneous Revascularization or Surgical Coronary Revascularization in Patients with CKD

Kidney International Reports(2021)10.1016/j.ekir.2021.03.882
Top 45%
0.414DataRank
Top 45%7 citations

Katya Zelevinsky, Robert Wolf, Sharon‐Lise T. Normand, David M. Charytan

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Kidney International(2020)10.1016/j.kint.2020.10.042
N/A
0DataRank · unranked
160 citations

Meg Jardine, Rajiv Agarwal, George L. Bakris, Christopher P. Cannon, David M. Charytan +15 more

The Association of Ejection Fraction With Hospital-Associated Cardiac Arrest and Heart Failure Hospitalization Differs According to Baseline Estimated GFR

Kidney International Reports(2023)10.1016/j.ekir.2023.08.030
N/A
0DataRank · unranked
2 citations

David M. Charytan, David M. Charytan, Finnian R. Mc Causland, Katherine Scovner Ravi

Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

Diabetes Care(2024)10.2337/dc23-1450
N/A
0DataRank · unranked
12 citations

David M. Charytan, Harpreet S. Bajaj, Adeera Levin, Navdeep Tangri, April Slee +6 more